| S1707 |
Eplerenone
|
Eplerenone是一类mineralocorticoid receptor 拮抗剂，阻断了醛固酮的作用，用于控制高血压。 |
-
Biomolecules, 2025, 1509
-
J Immunother Cancer, 2024, 12(11)e009805
-
Acta Pharm Sin B, 2023, 13(2):662-677
|
|
| E0704 |
Esaxerenone (CS-3150)
|
Esaxerenone (CS-3150)是一种选择性非甾体盐皮质受体(nonsteroidal mineralocorticoid receptor, MR)拮抗剂，与盐皮质受体结合，抑制(3)H-醛固酮与盐皮质受体结合，IC50为9.4 nM。Esaxerenone (CS-3150)增加蛋白尿恢复到正常水平的可能性，并减少蛋白尿进展到更高水平。 |
-
Cell Death and Disease, 2021, 109
|
|
| E1239 |
Apararenone
|
Apararenone (MT-3995) 是一种选择性的长效非甾体盐皮质激素受体(mineralocorticoid receptors, MR)拮抗剂。 |
|
|
| S5273 |
Canrenone
|
Canrenone (Aldadiene, SC-9376, RP-11614, 6,7-Dehydro-7α-desthioacetylspironolactone), a cardiovascular drug, a sort of steroid, is spironolactone's major metabolite and has been widely used as a nonselective aldosterone receptor antagonist clinically to treat heart failure, high blood pressure, edema, liver ascites, and other cardiovascular diseases. |
|
|
| S9702 |
Finerenone (BAY 94-8862)
|
Finerenone (FIN, BAY 94-8862) 是一种高度选择性的、口服活性的 mineralocorticoid receptor (MR) 的非甾体拮抗剂，IC50值为18 nM。Finerenone 具有研究诸如2型糖尿病和慢性肾脏病等心肾疾病的潜力。 |
-
Biomolecules, October 25, 2025, 1509
-
Scientific Reports, November 21, 2025, 41378
-
Journal of the American Heart Association, April 16, 2026, nan
|
|
| S1707 |
Eplerenone
|
Eplerenone是一类mineralocorticoid receptor 拮抗剂，阻断了醛固酮的作用，用于控制高血压。 |
- Biomolecules, 2025, 1509
- J Immunother Cancer, 2024, 12(11)e009805
- Acta Pharm Sin B, 2023, 13(2):662-677
|
|
| E1239 |
Apararenone
|
Apararenone (MT-3995) 是一种选择性的长效非甾体盐皮质激素受体(mineralocorticoid receptors, MR)拮抗剂。 |
|
|
| S5273 |
Canrenone
|
Canrenone (Aldadiene, SC-9376, RP-11614, 6,7-Dehydro-7α-desthioacetylspironolactone), a cardiovascular drug, a sort of steroid, is spironolactone's major metabolite and has been widely used as a nonselective aldosterone receptor antagonist clinically to treat heart failure, high blood pressure, edema, liver ascites, and other cardiovascular diseases. |
|
|
| S9702 |
Finerenone (BAY 94-8862)
|
Finerenone (FIN, BAY 94-8862) 是一种高度选择性的、口服活性的 mineralocorticoid receptor (MR) 的非甾体拮抗剂，IC50值为18 nM。Finerenone 具有研究诸如2型糖尿病和慢性肾脏病等心肾疾病的潜力。 |
- Biomolecules, October 25, 2025, 1509
- Scientific Reports, November 21, 2025, 41378
- Journal of the American Heart Association, April 16, 2026, nan
|
|
